Dallas, Texas-based Kimberly-Clark Corporation (KMB) manufactures personal care and consumer tissue products in the U.S. and internationally. With a market cap of $49.6 billion, Kimberly-Clark operates through the Personal Care, Consumer Tissue, and K-C Professional segments.
Companies worth $10 billion or more are generally described as "large-cap stocks," Kimberly-Clark fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size, influence, and dominance in the household & personal products industry. It has a portfolio of well-known brands, including Andrex, Cottonelle, Depend, Huggies, Kleenex, Plenitude, Poise, Scott, and more.
Kimberly-Clark touched its 52-week high of $149.30 on Sep. 5, and it's now trading 2% below that peak. KMB gained 8% over the past three months, outpacing the Nasdaq Composite’s ($NASX) marginal decline during the same time frame.
Over the longer term, KMB has underperformed NASX. KMB gained 14.7% over the past 52 weeks, lagging behind NASX’s 23.7% surge during the same time frame. However, in 2024, KMB rallied 20.4%, outperforming NASX’s 13.4% returns on a YTD basis.
To confirm the bullish trend, KMB has traded above its 50-day moving average since early March and above its 200-day moving average since late March with slight fluctuations.
Shares of Kimberly-Clark dipped 5.7% after the release of its Q2 earnings on Jul. 23. The company’s top line declined 2.1% annually to $5 billion, falling short of analysts’ expectations.
However, Kimberly-Clark reported a robust 18.8% growth in adjusted EPS, reaching $1.96, and surpassed the consensus estimates by 16.7%. Despite the initial setback, KMB stock rebounded 3.4% in the subsequent trading session and maintained a positive momentum over the subsequent two sessions.
Kimberly-Clark’s competitor, Colgate-Palmolive Company (CL), has substantially outperformed KMB. CL gained 46% over the past 52 weeks and 34% in 2024.
Among the 19 analysts covering the KMB stock, the consensus rating is a “Moderate Buy.” The mean target price of $146.67 represents a marginal upside from current price levels.
On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
